EnClear Therapies
encleartherapies.com
Actively hiring
Rare Disease Therapeutics
Neurology & CNS Therapeutics
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$10.7M
5 rounds on record
Latest round
$718k
Venture round · Feb 2024 · 2 yr ago
Team
4
US Form 5500 (plan participants) · Dec 2025 · 0% in a year
Grants
$4.1M
3 grants · CORDIS
Backers
1
VU Venture Partners
The money's age
Long since its last round
31 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 1, 2025
Won a grant $3M · CORDIS
Jul 1, 2024
Won a grant $554k · CORDIS
Jan 1, 2024
Won a grant $588k · CORDIS
Feb 19, 2020
Raised a round Series A $10M
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jan 2025 | $3M | — | CORDIS |
| Grant | Jul 2024 | $554k | — | CORDIS |
| Venture round | Feb 2024 | $718k | — | SEC Form D |
| Grant | Jan 2024 | $588k | — | CORDIS |
| Series A | Feb 2020 | $10M | — | reuters.com |
Registers and programsofficial lists and records that name the company
| Legal entity | EnClear Therapies, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Anthony DePasquaExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
VU Venture Partners Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Our Mission. Deliver medicines that transform the lives of patients with neurodegenerative diseases.
We’re building a pipeline of next-generation therapeutics focused on broadening the treatment paradigm for migraine and other headache…
Boldly advancing the next generation of medicines for Alzheimer’s Disease and Related Dementias.
Restoring energy. Next-generation disease-modifying medicines for ALS and Parkinson's.
AAVantgarde is a clinical-stage biotechnology company developing next-generation therapies for inherited retinal diseases with high unmet…
Top of page Memsel: Pioneering Pathways in Biotechnology Discover Our Mission, Partners, and Opportunities - Building Collaborations for a…
News
EnClear Therapies, Inc. Secures Additional Funding to Advance Neuro-Oncology Innovations
Support from the Brain Tumor Investment Fund, a subsidiary of the National Brain Tumor Society, and Sontag Innovation Fund Strengthens Efforts in Pre-Clinical Development. CAMBRIDGE, MA / ACCESSWIRE / September 3, 2024 / EnClear Therapies, Inc., an ...
Read more
Report
Report
People
Anthony DePasqua
Executive Officer, Director
Jonathan Fleming
Director
Jason Camm
Director
Kasper Roet
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
50-200 est. staff